Key result
Increased post-chemotherapy tumor volume is linked to a ~27-month shorter disease-free survival versus stable volume.
Why the study?
Change in tumor volume after chemotherapy appears to have prognostic significance for the outcome of osteosarcoma but requires validation with a reproducible measurement method.
Does tumor volume change after chemotherapy predict disease free survival in patients with osteosarcoma?
Observational (n=38)
No
Does tumor volume change after chemotherapy predict disease free survival in patients with osteosarcoma?
Tumor volume change measured by 3D MRI after preoperative chemotherapy is a significant predictor of disease-free survival in osteosarcoma patients.
Answers are grounded in this paper and cite their sources.
May refine osteosarcoma risk stratification post-chemotherapy; leaves open prospective validation before guiding therapy.
Change in tumor volume after chemotherapy appears to have a prognostic significance for the outcome of osteosarcoma. A newly developed volume measurement method based on three-dimensional summation with a proved reproducibility was utilized to measure osteosarcoma tumor volume. This retrospective analysis included 38 patients with biopsy- proven, nonsurface, skeletal high-grade osteosarcoma. The treatment was started by using three cycles of preoperative chemotherapy with cisplastin (100 mg/m2) and adriamycin (30 mg/m2). The tumor volume was measured before and after preoperative chemotherapy using three-dimensional magnetic resonance image measurement. The percentage of tumor necrosis was assessed by pathologic exam. After three cycle of postoperative chemotherapy, the patients were followed up at regular interval. For the 23 good responder patients, the mean survival time was 73.2 months (95% confidence interval 61.9-84.5 months), and for the 15 poor responder patients, the mean survival time was 50.8 months (95% confidence interval 38.6-63.1 months) (p<0.05). For the 14 patients with increased tumor volume after chemotherapy, the mean survival time was 47.5 months (range: 36.3-58.6 months) and for the 24 patients with stable or decreased tumor volume, the mean survival time was 74.3 months (range: 63.79-84.88 months) (p<0.05). Among the various factors, histopathologic response and tumor volume change after chemotherapy predicted disease free survival (p<0.05). Change in the tumor volume that was measured with a reproducible method and the histopathologic response after chemotherapy were the important predictors of disease free survival for osteosarcoma patients.
No takes yet. Share an insight, caveat, or question.
Moon et al. (2005) conducted an observational in Osteosarcoma (n=38). Increased tumor volume after preoperative chemotherapy vs. Stable or decreased tumor volume was evaluated on Mean disease free survival time (p=<0.05). Increased tumor volume after preoperative chemotherapy significantly reduced mean disease-free survival to 47.5 months compared to 74.3 months for stable or decreased tumor volume.
Synapse has enriched 10 related papers. Consider them for comparative context: